|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8536122||NOVO||Acylated GLP-1 compounds|| |
(2 years from now)
|US8129343||NOVO||Acylated GLP-1 compounds|| |
(8 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9764003||NOVO||Use of long-acting GLP-1 peptides|| |
(9 years from now)
|US10888605||NOVO||GLP-1 compositions and uses thereof|| |
(14 years from now)
|US11318191||NOVO||GLP-1 compositions and uses thereof|| |
(17 years from now)
Wegovy is owned by Novo.
Wegovy contains Semaglutide.
Wegovy has a total of 5 drug patents out of which 0 drug patents have expired.
Wegovy was authorised for market use on 04 June, 2021.
Wegovy is available in solution;subcutaneous dosage forms.
Wegovy can be used as method for weight management, method for weight management according to a dose escalation schedule.
The generics of Wegovy are possible to be released after 17 February, 2041.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Product (NP)||Jun 4, 2024|
|New Patient Population (NPP)||Dec 23, 2025|
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management according to a dose escalation schedule; Method for weight management
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic